Interval Debulking Surgery Is Less Invasive Than Upfront Debulking Surgery for Stage III/IV Cancers (ovarian/PP/FT)
Ovarian Cancer and Us
OVARIAN CANCER and US
Ovarian Cancer and Us
In a phase III trial, the standard treatment (primary debulking
surgery) was compared with neoadjuvant chemotherapy (including interval
debulking surgery) for patients with stage III/IV ovarian, tubal, and
peritoneal cancers. Neoadjuvant therapy led to fewer surgeries, reduced
operation time, less organ resection, less blood loss, fewer albumin
transfusions, and fewer high-grade adverse events following surgery.
Neoadjuvant therapy is less invasive than the standard treatment for
advanced ovarian cancer and may become the new standard if
noninferiority is confirmed.
0
comments
:
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.